Objective To explore the correlation between the blood concentration of voriconazole and risks of adverse drug reactions in chronic obstructive pulmonary disease(COPD)patients suffering from pulmonary infection.Methods A total of 144 COPD patients who received treatment with voriconazole from January 2022 to December 2023 were selected as the subjects and their trough concentration of voriconazole were detected by high performance liquid chromatography.Then these patients were divided into high trough concentration group(n=27),medium trough concentration group(n=71)and low trough concentration group(n=46).The relationship between incidence of adverse drug reactions and blood drug concentration were analyzed in all the 3 groups.Results The overall efficiency of voriconazole was 81.94%.The clinical response rate in the low trough concentration group(69.57%)was lower than that in the other 2 groups(81.48%and 90.14%,respectively),with a statistically significant difference(P<0.05).The incidence of adverse reactions was 17.36%,including 14 cases of drug-induced liver damage(6 cases of elevated alanine aminotransferase)and 11 cases of hallucinations,dreaminess and delirium.The incidence of adverse drug reactions was statistically significant among the 3 groups(29.63%,16.90%,and 10.87%,respectively)(P<0.05).Conclusion The trough concentration of fluconazole between 1.0 and 5.5 μg·mL-1 shows high response rate and relatively low incidence of adverse drug reactions.Monitoring the blood concentration of voriconazole is significant for guiding clinical medication and plays an key role in improving efficacy and reducing adverse reactions.
Chronic obstructive pulmonary diseaseDrug monitoringVoriconazoleBlood drug concentrationAdverse reaction
NETL
NSTL
万方数据
